Metabolic Syndrome and Cardiovascular Risk in Women With  Polycystic Ovary Syndrome: An Integrative Review of Mechanisms,  Clinical Evidence, Real-World Data and Precision Prevention

Xolboyeva Mashhura

Authors

Xolboyeva Mashhura

Keywords:

polycystic ovary syndrome; metabolic syndrome; cardiovascular disease; insulin resistance; hyperandrogenism; dyslipidemia; glucose tolerance; type 2 diabetes; obesity; real-world evidence; artificial intelligence; preventive cardiology; clinical epidemiology.

Abstract

Polycystic ovary syndrome (PCOS) is a heterogeneous endocrine disorder with consequences extending beyond ovulatory function and androgen excess. Metabolic syndrome, impaired glucose tolerance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular morbidity are important dimensions of long-term care. Objective: To critically integrate evidence linking PCOS to metabolic syndrome and cardiovascular risk, distinguish established associations from unresolved causal pathways, and assess opportunities for real-world evidence and artificial intelligence in prevention.

Downloads

Download data is not yet available.

References

1. Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463.

2. Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril. 2023;120(4):767-793. doi:10.1016/j.fertnstert.2023.07.025.

3. 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: nsights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome. PubMed PMID:39119982. Available from: https://pubmed.ncbi.nlm.nih.gov/39119982/.

4. Risk and incidence of cardiovascular disease associated with polycystic ovary syndrome. Eur J Prev Cardiol. 2024. doi:10.1093/eurjpc/zwae066. PubMed PMID:38373259.

5. US Food and Drug Administration. Real-World Evidence [Internet]. Silver Spring (MD): FDA; [cited 2026 Oct 16]. Available from: https://www.fda.gov/scienceresearch/science-and-research-special-topics/real-world-evidence.